Overview
- An internal memo reported by CNBC shows Tracy Beth Høeg is out as acting head of the Center for Drug Evaluation and Research, with Karim Mikhail stepping in as acting director.
- Michael Davis will lead the Center for Biologics Evaluation and Research on an acting basis as Katherine Szarama exits that role but remains at the agency.
- The FDA updated its public org chart to reflect the new lineup, signaling the changes are in effect.
- Kyle Diamantas is serving as acting FDA commissioner after Marty Makary resigned earlier in the week over disputes that included e‑cigarette policy.
- Høeg drew scrutiny for questioning FDA decisions on RSV infant treatments, opposing a fast‑track for Sanofi’s teplizumab, and co‑authoring work used to justify a vaccine‑schedule overhaul that a judge later paused.